• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology.

作者信息

Jessica Chang Ting Yi, Pope Janet E

机构信息

Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON N6A 3K7, Canada.

Division of Rheumatology, St Joseph's Health Care London, London, ON N6A 4V2, Canada.

出版信息

Immunotherapy. 2020 Oct;12(15):1115-1119. doi: 10.2217/imt-2020-0153. Epub 2020 Jul 9.

DOI:10.2217/imt-2020-0153
PMID:32640861
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7346716/
Abstract
摘要

相似文献

1
How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology.新型冠状病毒肺炎如何影响在风湿病学和皮肤病学中接受抗细胞因子和JAK抑制剂治疗的患者。
Immunotherapy. 2020 Oct;12(15):1115-1119. doi: 10.2217/imt-2020-0153. Epub 2020 Jul 9.
2
JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk.JAK 抑制剂在 COVID-19 中的应用：警惕固有血栓形成风险增加的必要性。
Eur Respir J. 2020 Sep 24;56(3). doi: 10.1183/13993003.01919-2020. Print 2020 Sep.
3
Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?巴瑞替尼、JAK抑制剂与肝损伤：新冠疫情中值得关注的问题？
Expert Opin Drug Saf. 2020 Oct;19(10):1367-1369. doi: 10.1080/14740338.2020.1812191. Epub 2020 Aug 25.
4
[Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].[在重症新型冠状病毒肺炎患者中使用JAK 1/2抑制剂的理论依据]
Ugeskr Laeger. 2020 Jun 15;182(25).
5
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.免疫介导性炎症疾病中的新冠病毒病——来自纽约的病例系列
N Engl J Med. 2020 Jul 2;383(1):85-88. doi: 10.1056/NEJMc2009567. Epub 2020 Apr 29.
6
The immediate impact of COVID-19 on US dermatology practices.2019冠状病毒病对美国皮肤科诊疗业务的直接影响。
J Am Acad Dermatol. 2020 Aug;83(2):685-686. doi: 10.1016/j.jaad.2020.05.048. Epub 2020 May 16.
7
Dermatology and COVID-19.皮肤病学与新型冠状病毒肺炎
JAMA. 2020 Sep 22;324(12):1133-1134. doi: 10.1001/jama.2020.15276.
8
Preliminary Data Suggests That Biologics in Dermatology Are Not Associated With Adverse COVID-19 Outcomes.初步数据表明，皮肤科使用的生物制剂与新冠肺炎不良结局无关。
J Cutan Med Surg. 2020 Jul/Aug;24(4):420-421. doi: 10.1177/1203475420929250. Epub 2020 May 25.
9
Optimizing education for dermatology residents during the COVID-19 pandemic.在新冠疫情期间优化皮肤科住院医师培训
J Am Acad Dermatol. 2020 Oct;83(4):e319-e320. doi: 10.1016/j.jaad.2020.07.029. Epub 2020 Jul 16.
10
Comment on "Dermatology residents and the care of COVID-19 patients".对《皮肤科住院医师与新冠肺炎患者的护理》的评论
J Am Acad Dermatol. 2020 Jul;83(1):e49. doi: 10.1016/j.jaad.2020.04.071. Epub 2020 Apr 21.

引用本文的文献

1
d-Dimer trend in a long-term rheumatoid arthritis patient with tofacitinib treatment and recent COVID-19 infection.一名长期使用托法替布治疗且近期感染新型冠状病毒肺炎的类风湿关节炎患者的D-二聚体变化趋势
Rev Colomb Reumatol. 2022 Jun;29:S84-S87. doi: 10.1016/j.rcreu.2021.06.003. Epub 2021 Jul 5.
2
Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity.性别的药理学和 COVID-19：迈向适当性和健康公平的下一步。
Pharmacol Res. 2021 Nov;173:105848. doi: 10.1016/j.phrs.2021.105848. Epub 2021 Aug 26.
3
An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology.皮肤科接受免疫治疗患者的 SARS-CoV-2 疫苗接种的循证指南。
J Am Acad Dermatol. 2021 Jun;84(6):1652-1666. doi: 10.1016/j.jaad.2021.01.047. Epub 2021 Jan 19.
4
COVID-19 and the newly rediscovered multidisciplinarity.新冠疫情与新发现的多学科交叉性
Immunotherapy. 2020 Oct;12(15):1101-1103. doi: 10.2217/imt-2020-0205. Epub 2020 Sep 21.

本文引用的文献

1
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.在患有新冠肺炎、急性呼吸窘迫综合征和炎症反应过度的患者中使用高剂量阿那白滞素进行白细胞介素-1阻断：一项回顾性队列研究。
Lancet Rheumatol. 2020 Jun;2(6):e325-e331. doi: 10.1016/S2665-9913(20)30127-2. Epub 2020 May 7.
2
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者因 COVID-19 住院的相关特征：来自 COVID-19 全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.
3
Hydroxychloroquine shortages during the COVID-19 pandemic.2019冠状病毒病大流行期间羟氯喹的短缺情况。
Ann Rheum Dis. 2021 Mar;80(3):e31. doi: 10.1136/annrheumdis-2020-217835. Epub 2020 May 20.
4
HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.抑制 JAK 酶治疗 SARS-CoV-2？JAK 抑制剂在 COVID-19 治疗中的潜在作用。
Sci Immunol. 2020 May 8;5(47). doi: 10.1126/sciimmunol.abc5367.
5
SARS-CoV-2 infection among patients with systemic autoimmune diseases.系统性自身免疫性疾病患者中的 SARS-CoV-2 感染。
Autoimmun Rev. 2020 Jul;19(7):102575. doi: 10.1016/j.autrev.2020.102575. Epub 2020 May 5.
6
COVID-19: a case for inhibiting IL-17?COVID-19：抑制白细胞介素-17（IL-17）的理由？
Nat Rev Immunol. 2020 Jun;20(6):345-346. doi: 10.1038/s41577-020-0328-z.
7
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
8
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.免疫介导性炎症疾病中的新冠病毒病——来自纽约的病例系列
N Engl J Med. 2020 Jul 2;383(1):85-88. doi: 10.1056/NEJMc2009567. Epub 2020 Apr 29.
9
Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis.结缔组织病患者中新型冠状病毒肺炎的发病率及临床病程：一项描述性观察分析
J Rheumatol. 2020 Aug 1;47(8):1296. doi: 10.3899/jrheum.200507. Epub 2020 Apr 25.
10
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact.巴瑞替尼治疗新冠肺炎：一项关于安全性和临床影响的初步研究。
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.04.017. Epub 2020 Apr 23.